Rubicon Research IPO

rubicon ipo

    Open an Account Now!

    By signing up, you agree to receive updates on SMS, Email & Whatsapp

    Rubicon Research IPO

    Rubicon Research is a  pharmaceutical  formulations  company,  driven  by  innovation  through  focused  research  and  development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of six listed Indian companies assessed by F&S, and the Company), it is the only Indian pharmaceutical player with a complete focus on regulated markets.
    Apply IPO Online

    Rubicon Research IPO Details

    Opening Date

    9 Oct'2025

    Closing Date

    13 Oct'2025

    Price Band

    ₹461 to ₹485 per share

    Issue Size

    ₹1,377.50 Cr

    Face Value

    ₹1 per share

    Market Lot

    30 Shares

    Listing at NSE,BSE

    Rubicon Research IPO Timeline (Tentative Schedule)

    IPO Open Date 9 Oct'2025
    IPO Close Date 13 Oct'2025
    Allotment Date 14 Oct'2025
    Initiation Of Refunds 15 Oct'2025
    Credit Of Shares To
    Demat Account    		 15 Oct'2025
    IPO Listing Date 16 Oct'2025
    UPI Mandate Expiry Date 13 Oct'2025

    Checkout the List of Upcoming IPO

    Financial Highlights

    Period Ended 30 Jun 2025 31 Mar 2025 31 Mar 2024 31 Mar 2023
    Assets 1,647.60 1,451.43 1,109.49 749.70
    Total Income 356.95 1,296.22 872.39 419.00
    Profit After Tax 43.30 134.36 91.01 -16.89
    EBITDA 79.74 267.89 173.09 43.97
    NET Worth 593.67 540.98 385.00 286.38
    Reserves and Surplus 397.50 525.57 369.79 281.31
    Total Borrowing 495.78 393.17 396.41 317.91

    Strengths & Weakness

    Strengths Weaknesses
    Fastest growing Indian pharmaceutical company amongst its peers and the only Indian company focused completely on the US market. Manufacturing complexities and regulatory issues may impact sales, delay product launches, harm operations, or even lead to facility closures.
    Data-driven framework enables it to build a diverse product portfolio, balancing new and specialty products to withstand pricing pressures. Disruptions to R&D or manufacturing facilities can significantly impact business, operations, and cash flow.
    Robust sales and distribution capabilities in the US. Company’s success relies on executing growth strategies; failure to sustain or manage growth may harm business and financial health.
    Strong track record of compliance combined with expertise in cost effective manufacturing. Intense competition in the pharmaceutical industry could harm business and future growth prospects.

    How to apply in IPO via UPI on Dynami

    A simple and smartest way to Apply in IPO online via Religare Dynami Mobile App

    How to apply for Rubicon Research IPO?

    Retail investors need to apply for the IPO using UPI

    UPI

    • Link your bank account to a UPI ID.
    • Register your UPI id with your Demat account.
    • Subscribe for Rubicon Research IPO and approve the payment on your UPI ID.

    Demat Account

    How to open a
    Demat & Trading Account?

    Demat & Trading Account
    Form fill up Demat & Trading Account

    Fill up your personal details in the form above

    Share Personal Details Demat & Trading Account

    Fill up your DOB, PAN, email & bank account details

    OTP Authentication Demat & Trading Account

    Upload your photo and e-sign your application via Aadhaar OTP

    Open Demat Account

    Frequently Asked Questions

    The issue size for Rubicon Research IPO is ₹1,377.50 Cr
    You can apply for the Rubicon Research IPO 2 days before the official subscription period begins using the pre-apply option.
    Pre-applying for the Rubicon Research IPO lets you apply before it officially opens. Click on the Apply Now link to apply for Rubicon Research IPO on Religare Broking.
    Your order will be submitted to the exchange as soon as bidding for Rubicon Research begins. You will receive a UPI request within 24 hours after the bidding starts.
    We will notify you when your Rubicon Research.order is placed with the exchange.
    The open date is 9 Oct’2025 and the closing date is 13 Oct’2025.
    The lot size of the IPO is 30 shares
    The price band of the IPO is ₹461 to ₹485 per share

    To remain updated on the latest
    market updates     follow us at

    Copyright 2025 Religare. Trademarks are the property of their respective owners. All rights reserved. Please note that by submitting your mobile and email on our website, you are authorizing us to Call/SMS/Whtsapp/Email you even though you may be registered under the DNC. We shall Call/SMS you for a period of 6 months.

    Religare Broking Limited (CIN: U65999DL2016PLC314319) Registered Office: Religare Broking Limited, 802 -815B, 8th Floor, Gopal Das Bhawan, 28-Barakhamba Road, Connaught Place, New Delhi - 110001. Board line number: +91-011-49871213, Fax No. +91-011-49871189. Member Religare Broking Limited (RBL) : SEBI Regn. No. INZ000330135 NSE CM, F&O, CD TM Code: 06537 Clearing Member (F&O) No. M50235; BSE CM, F&O, CD, CO Code: 3004 Clearing No: 3004; MSE CM, F&O, CD, TM Code: 1051| MCX Membership No. 56560 | NCDEX Membership No. 01276 | AMFI ARN No.139809. Depository Participant : Religare Broking Limited (RBL) – NSDL: DP ID: IN 301774 | SEBI Regn. No: IN-DP-385-2018 | CDSL DP ID: 30200 | SEBI Regn. No: IN-DP-385-2018. Research Analyst: Religare Broking Limited (RBL) – SEBI Regn. No: INH100006977 | BSE Ltd. (RAASB) Enlistment No. 5334 | Registrars to an issue and share Transfer Agents (RTA) - SEBI Regi. No : INR000004361 | Corporate Agent (Composite) - IRDA Regi. No : CA0581 | National Pension System - Point of Presence (NPS-POP) - PFRDA Regi. No : POP01092018.

    Disclaimer: Investments in the securities market are subject to market risks, read all the related documents carefully before investing. RBL is a distributor of Mutual Funds / IPOs / Insurance / Bonds & NCDs / Corporate FDs etc. Equities, Currencies & Depository Services are offered through Religare Broking Ltd. All disputes with respect to the distribution activity / Insurance services would not have access to Stock Exchanges investor redressal forum or Arbitration mechanism. The securities are quoted as an example and not as a recommendation | https://religareonline.com/disclaimer